XmAb-18968

N/A

Report date: 2026/03/19 17:22:27

Base Information

Drug NameXmAb-18968

Drug Alias NameXmAb-18968

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers

Mechanisms of ActionAnti-CD38Anti-CD3

TargetsLymphocyte differentiation antigen CD38T cell surface glycoprotein CD3

Therapy Area/IndicationsLeukemia, Myeloid, Acute

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesThe Medical College Of Wisconsin Nonprofit

China Registration ClassN/A

Develop Information

Active CompaniesThe Medical College Of Wisconsin Nonprofit

Inactive CompaniesN/A

Active IndicationsLeukemia, Myeloid, Acute

Inactive IndicationsN/A

Other Information

ATC CodeN/A